MOLÉCULES BISPÉCIFIQUES PRÉSENTANT UNE IMMUNORÉACTIVITÉ PAR RAPPORT À TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR 2 ET À CADHERIN 17 POUR LE TRAITEMENT DU CANCER
This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.